Literature DB >> 11562816

[RecDate - an IT-solution for the documentation and quality management of reproductive medicine].

S J Pak1, J Warlich, T N van Rooij.   

Abstract

OBJECTIVES: The aim of this paper was to describe the possible use of the software RecDate für documentation and Quality Management in Reproductive Medicine.
MATERIAL AND METHODS: RecDate was programmed using the data base program Filemaker Pro. The functions and potentials of RecDate were analyzed.
RESULTS: RecDate enables the collection, documentation and evaluation of data from Reproductive Medicine and also functions as a hospital management tool.
CONCLUSIONS: The present status of Reproductive Medicine can be described by the use of RecDate in IVF-clinics, which is important for consulting and treatment of couples, for the quality of public enlightenment and for optimizing the processes in daily routine.

Entities:  

Mesh:

Year:  2001        PMID: 11562816     DOI: 10.1055/s-2001-17250

Source DB:  PubMed          Journal:  Zentralbl Gynakol        ISSN: 0044-4197


  5 in total

1.  A 2:1 formulation of follitropin alfa and lutropin alfa in routine clinical practice: a large, multicentre, observational study.

Authors:  Klaus Bühler; Olaf Naether
Journal:  Gynecol Endocrinol       Date:  2010-09-17       Impact factor: 2.260

2.  Multicenter, noninterventional, post-marketing surveillance study to evaluate dosing of recombinant human follicle-stimulating hormone using the redesigned follitropin alfa pen in women undergoing ovulation induction.

Authors:  Frank Nawroth; Andreas Tandler-Schneider; Wilma Bilger
Journal:  Drug Healthc Patient Saf       Date:  2015-04-15

3.  Individualized recombinant human follicle-stimulating hormone dosing using the CONSORT calculator in assisted reproductive technology: a large, multicenter, observational study of routine clinical practice.

Authors:  Olaf Gj Naether; Andreas Tandler-Schneider; Wilma Bilger
Journal:  Drug Healthc Patient Saf       Date:  2015-04-15

4.  Comparative effectiveness of recombinant human follicle-stimulating hormone alfa (r-hFSH-alfa) versus highly purified urinary human menopausal gonadotropin (hMG HP) in assisted reproductive technology (ART) treatments: a non-interventional study in Germany.

Authors:  Klaus F Bühler; Robert Fischer; Patrice Verpillat; Arthur Allignol; Sandra Guedes; Emmanuelle Boutmy; Wilma Bilger; Emilia Richter; Thomas D'Hooghe
Journal:  Reprod Biol Endocrinol       Date:  2021-06-16       Impact factor: 5.211

5.  A large, multicentre, observational, post-marketing surveillance study of the 2:1 formulation of follitropin alfa and lutropin alfa in routine clinical practice for assisted reproductive technology.

Authors:  Klaus Bühler; Olaf G J Naether; Wilma Bilger
Journal:  Reprod Biol Endocrinol       Date:  2014-01-14       Impact factor: 5.211

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.